Contact Us
 • 
Home
Search 

Clinical Trials > Translational

Please click on a Trial Title for more information


ESPAC-Tplus A Translational Study, Characterisation of Tumour Molecular Response Predictors of Chemotherapy and Radiotherapy Treatments for Pancreatic Cancer in Patients in the ESPAC Trials

The ESPAC-1 trial has shown that pancreatic ductal adenocarcinoma is responsive to adjuvant chemotherapy (5FU). The ESPAC-1 trial has shown that pancreatic ductal adenocarcinoma is responsive to adjuvant chemotherapy (5FU). The ESPAC-3 trial is now comparing adjuvant 5-FU and gemcitabine.
ESPAC-TPlus was funded by the Translational Research in Clinical Trials Committee (TRICC) of Cancer Research UK in order to enable high quality translational research to be embedded in the ESPAC trials. ESPAC-TPlus is designed to allow both prospective and retrospective sample collection and analysis.
It is likely that some patients will respond better to adjuvant 5-FU than gemcitabine following resection for pancreatic ductal adenocarcinoma, while others will respond better to gemcitabine. Survival of an individual patient will therefore depend on which treatment they are given, but at present a clinician has very little information on which to base the choice of treatment.
Pancreatic tumours are highly characterised in molecular terms facilitating molecular taxonomy of these tumours and the identification of predictive therapeutic response molecular signatures. ESPAC-3 trial is now comparing adjuvant 5-FU and gemcitabine.

All recruitment and site information is updated hourly from LCTU systems